Noxafil is an azole antifungal indicated as follows:
• Noxafil injection and Noxafil delayed-release tablets are indicated
for the treatment of invasive aspergillosis in adults and pediatric
patients 13 years of age and older.
• Noxafil is indicated for the prophylaxis of invasive Aspergillus and
Candida infections in patients who are at high risk of developing these
infections due to being severely immunocompromised, such as
hematopoietic stem cell transplant (HSCT) recipients with graftversus-
host disease (GVHD) or those with hematologic malignancies
with prolonged neutropenia from chemotherapy as follows:
o Noxafil injection: adults and pediatric patients 2 years of age and
older
o Noxafil delayed-release tablets: adults and pediatric patients 2
years of age and older who weigh greater than 40 kg
o Noxafil oral suspension: adults and pediatric patients 13 years
of age and older
o Noxafil PowderMix for delayed-release oral suspension:
pediatric patients 2 years of age and older who weigh 40 kg or
less
• Noxafil oral suspension is indicated for the treatment of
oropharyngeal candidiasis (OPC), including OPC refractory (rOPC) to
itraconazole and/or fluconazole in adult and pediatric patients aged
13 years and older.
